Groundbreaking ARM Shot Set to Redefine Cancer Therapies

On behalf of Defence Therapeutics Inc.

Brace yourselves.

Cancer—a word that chills the spine. It doesn’t discriminate, hitting the young and the robust. Disturbing facts from BMJ Oncology report a staggering 79% rise in early-onset cases in the last 30 years.¹

The culprits? Windpipe and prostate cancer, leading the surge.

Imagine enduring chemotherapy—the months of recuperation, the relentless side effects—fatigue, nausea, you name it. It’s a brutal journey, a test of grit and resilience. But there’s a flicker of light on the horizon.

Take Adrian Taylor²—a living beacon of newfound hope. Facing a grim prognosis, he gambled on a pioneering cancer jab trial last November.

Today? He’s not just surviving; he’s thriving, cherishing milestones with his family. A testament to the sheer power of innovation.

Picture this: A powerhouse forging ahead, reshaping the biopharmaceutical terrain with groundbreaking cancer shots. This isn’t just a pipe dream—it’s a tangible, gripping reality, and one enterprise is spearheading this revolution.

Welcome to the realm of Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), a disruptor pioneering a technological approach to cancer treatment. Leveraging its groundbreaking Accum® Technology, it’s gearing up to tackle even the toughest cancer adversaries.

We’re standing at the cusp of a medical renaissance, an era where hope and science converge. Keep your eyes peeled—this is where the future unfolds.

Using its patented and highly versatile state-of-the-art Accum™ Technology, Defence Therapeutics focuses on targeting the most difficult types of cancers to treat.

Breaking News

Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology

Unlike chemotherapy, which damages and kills healthy cells along with the cancerous ones, Accum® has now proven its ability to deliver treatments³ – to the infected parts of infected cells only – at 10x the rate of current (ADC) solutions by:

Accumulating more ADCs into a target cell
Breaking the endosomal membrane
Successfully reaching intracellular target sites
Delivering more of the intended medication to the intended sites (only)

As a testament to its ground-breaking work, Defence Therapeutics recently collaborated with Viewpoint with Dennis Quaid (a highly acclaimed short-form series)⁴ to bring awareness to this vital mission.⁵

Viewpoint with Dennis Quaid and Defence Therapeutics Join Forces to Explore Breakthroughs in Biotechnology – Watch Now!

Significantly, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is at a crucial turning point: it’s transitioning from discovery to the clinical stage, gearing up for two Phase 1 clinical trials for its patented cancer shot and anti-cancer therapeutics.⁶

Now charging forward, Defence Therapeutics is on the path toward filing an IND (Investigational New Medicine) application with the FDA.⁷

It’s time to delve into why Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) stands as a beacon, on the threshold of crafting groundbreaking shots that could redefine survival for millions.

7 Reasons

to Add Defence Therapeutics (CSE:DTC) (OTC:DTCFF) To Your Watchlist

Groundbreaking Patented Technology Platform: Defence Therapeutics’ (CSE:DTC) (OTC:DTCFF) US-patented Accum® Technology platform delivers enhanced intracellular treatment delivery, with a versatility targeting multiple cancers, especially those difficult to treat. This technology can elevate the potency of any Defence Therapeutics or partner product by at least 10-20X.⁸

Significant Traction and Pipeline: Defence Therapeutics is leveraging Accum® Technology with two programs in cancer treatment and cancer shot development, each showcasing significant progress.

Robust IP Portfolio: Defence Therapeutics (CSE:DTC) (OTC:DTCFF) boasts a global IP portfolio, with 7 distinct patent families surrounding four central functions related to ADCs, RNA, DNA, MSCs, mRNA, Delivery, Mixing, Linking, Gene Editing, and CRISPR/Cas9. This opens the door for global licensing opportunities.

Favorable Capital Structure: Defence Therapeutics (CSE:DTC) (OTC:DTCFF) has a solid foundation with 43 million shares outstanding. Notably, the trading float is only 22-25% of the total outstanding shares.

Extensive Experience: Led by a team with wide-ranging expertise in pre-clinical studies, clinical trials, business development, and regulatory compliance, ensuring a well-rounded approach, including Dr. Moutih Rafei, a world-renowned expert in immuno-oncology and Dr. Raimar Löbenberg, who founded the [Medicine] Development and Innovation Centre at the University of Alberta.

Gaining National Recognition with Viewpoint with Dennis Quaid Collaboration: Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) partnered with the nationally renowned show, Viewpoint, hosted by Dennis Quaid. The episode is airing across 170+ U.S. stations from September 18, 2023, spotlighting Defence’s cutting-edge biotech advancements.

Remarkable Preclinical Results: Defence Therapeutics (CSE:DTC) (OTC:DTCFF) has shown impressive preclinical results, with a 100% cure rate on pre-established Lymphoma and an 80% success rate on Melanoma.

Developing the First-of-its-Kind Scalable Solution Solving Previous Cancer Treatment Challenges

Dr. Moutih Rafei, a leader in the development of immune-related therapies for catastrophic illnesses, leads Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) into making new cancer and disease shots. Their secret weapon? The ACCUM® platform.

What Makes ACCUM® Stand Out?

The ACCUM® technology amplifies the potency of medications by an astonishing 10-20X compared to existing solutions, acting as a precision-targeted force that zeroes in exclusively on the harmful cells within your body. It’s a revolution in efficiency, potentially slashing medication costs, as a smaller amount packs a mightier punch, embodying the philosophy that less is indeed more when it’s this powerful.

Versatile Strategy, Singular Solution

In a world where most firms narrow their focus on battling a singular type of ailment, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) aims to transcend boundaries. While the conquest of cancer remains their paramount objective, the Company is also deploying forces against a spectrum of infectious diseases. Imagine a singular technology with the prowess to combat a range of threats, from cancer to Ebola and even CV-19.

Plus, the agility of this technology is unprecedented. ACCUM® stands ready to pivot swiftly, presenting a beacon of hope for faster, adaptable responses in the face of emergent global health crises, such as pandemics.

Enhanced Safety and Efficacy

A noteworthy advantage lies in the potential for ACCUM® technology to minimize side effects, acting akin to an intelligent weapon that selectively neutralizes adversaries while preserving the allies. Consequently, individuals could experience a more comfortable journey while undergoing treatment with these innovative medications.

Groundbreaking Trials in the Real World

Undeterred by challenges, Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) is advancing its ARM shots in trials against pancreatic and ovarian cancers—two ‘killers’ in the medical world. As highlighted earlier, preliminary trial results are promising, boasting a remarkable 100% cure rate in pre-established lymphoma cases, and an impressive 80% efficacy rate in melanoma pre-clinical trials. The fight is on, and the future looks brighter with each successful test.

image4 1 Groundbreaking ARM Shot Set to Redefine Cancer Therapies

Let’s take a quick look at how Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) compares to its other potential peers in the space:

DTC Chart 1 Groundbreaking ARM Shot Set to Redefine Cancer Therapies

In a world where many companies are trying to find a cure for cancer, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is like a special island with a hidden treasure. They have something really unique — the Accum® Technology.

This technology is not just an idea; it actually works! It helps make medicines up to 10 times stronger against the bad cells compared to other treatments that are already being used.

But the great part? Defence Therapeutics (CSE:DTC) (OTC:DTCFF) isn’t keeping this amazing discovery all to themselves. They want to share it with others. They are in talks with different companies to possibly share this technology, helping them improve their own medicines too.

Press Releases

What makes Accum® Technology really cool is that it amplifies the power of ADCs (highly targeted biopharmaceutical treatments) to deliver cancer-fighting treatments more efficiently and selectively to cancer cells, maximizing therapeutic impact while minimizing harm to healthy tissues.

In simpler words, it’s like having a super-smart GPS system just for cancer treatments, guiding them directly to the problem areas. And the first tests show that it’s really effective in stopping the growth of tumors!

Accelerated Cancer Shot Development on the Path Towards Approval

Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) is advancing with a formidable strategy to counteract some of the most lethal forms of cancer prevalent today. Leveraging the sophisticated Accum® technology, they have developed a pioneering formulation dubbed the ARM Shot. This isn’t just another arm jab; it’s meticulously designed to cultivate an immune response that adeptly identifies and eradicates malignant cancer cells.

image1 1 Groundbreaking ARM Shot Set to Redefine Cancer Therapies

image5 Groundbreaking ARM Shot Set to Redefine Cancer Therapies

Facing the Challenge of Pancreatic Cancer

In collaboration with Transbiotech Biotechnology Research, a vanguard in the Canadian biotech sector, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is taking significant strides in conducting trials on the ARM Shot against the formidable foe – pancreatic cancer.

As of 2023, this killer disease boasts a mortality rate of 78.9%, constituting 8.3% of total cancer fatalities.⁹ The upcoming tests will combine the ARM Shot with another treatment, bolstering the body’s defenses with the aspiration to demonstrate efficacy where conventional treatments have faltered.

image2 1 Groundbreaking ARM Shot Set to Redefine Cancer Therapies

Preparation for Clinical Phase I Trials Underway

Phase I trials are the next big step, and Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is working hard to get ready. They’re working with experts to decide the best dosing plans and are testing the shot under strict conditions to make sure it’s safe and effective. With everything going as planned, they aim to file an application with Health Canada by the fourth quarter of 2023. If they get the green light, this will set the stage for two big Phase I trials in 2024.

What’s Next?

Keep an eye out for the results of the dry runs and quality control steps, which are due by next spring. Once those are cleared, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) will get Health Canada’s approval and kick start their Phase I clinical trial in 2024. After that, this revolutionary ARM Shot could be adapted to treat various kinds of cancer, offering new hope to countless patients.

The future looks promising, and Defence Therapeutics is at the forefront of these medical breakthroughs. In short, it’s a journey worth watching.

US Patent Granted to Defence for Wide-Ranging Accum® Medicine Enhancer Tech

Recently, some exciting news came out. Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is about to start a Phase I clinical trial for AccuTOX™, focusing on skin cancer, also known as melanoma.¹⁰

This step forward was made possible thanks to a collaboration with Biopeptek Pharmaceuticals. But it’s not just skin cancer; AccuTOX™ has shown promise against other types, like lymphoma and breast cancer.¹¹ So, this treatment could be a game-changer in cancer care.

The US government has given the thumbs-up to Defence Therapeutics’s (CSE:DTC) (OTC:DTCFF) technology by granting them a patent.¹² This patent is like a golden ticket, letting them use their technology to fight not only cancer but also infectious diseases. It means they can make almost any shot work better, faster, and maybe even cheaper.

With its flexible Accum® technology, Defence Therapeutics (CSE:DTC) (OTC:DTCFF) is in a great spot to make a big impact, giving hope to many patients around the world.

Attractive Capital Structure with Loyal Investors and Partners

Let’s talk numbers. Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF) has 43,944,368 shares out there. But if we add in options, warrants, and finders warrants, the total comes to 48,924,268 shares. That’s the full picture.

image7 Groundbreaking ARM Shot Set to Redefine Cancer Therapies

What’s extra appealing is the float—the shares that people can actually buy and sell—is only around 22-25%. Why? Because most of the shares are held by wealthy, smart individuals who believe in Defence Therapeutics and plan to stick around for the long run.

This setup shows that Defence Therapeutics (CSE:DTC) (OTC:DTCFF) has strong support from people who have the money and know-how to invest wisely. They’re in it for the long game, and that says a lot about the company’s promise and stability.

Additionally, Defence is backed and supported by several significant partnerships, as listed below.

image6 2 Groundbreaking ARM Shot Set to Redefine Cancer Therapies

Big Pharma on a Buying Spree: Biotech Takeovers Poised to Soar

2023 is gearing up to be a powerhouse year for biotech mergers and acquisitions (M&A), with a jaw-dropping $43 billion deal already inked by March. Following 2022’s impressive tally of around $96.1 billion, the sector is clearly booming.¹³

Big pharma companies are hungrily eyeing young biotechs, keen to tap into their innovative approaches, especially in cancer research and other hot areas. Despite the steep acquisition premiums – averaging 85% in 2022 – these larger entities are ready to pay big, betting on the promising developments and substantial market gains these startups bring to the table.

Here are some of the biggest M&A deals in 2023:

Biogen acquired Reata Pharmaceuticals on July 28, 2023 for $7.3B at a 59% premium¹⁴
Eli Lilly acquired Dice Therapeutics on June 20, 2023 for $2.4B at a 42% premium¹⁵
Novartis acquired Chinook Therapeutics on July 20, 2023 for $3.2B at a 67% premium¹⁶
Sobi acquired CTI Biopharma on May 10, 2023 for $1.7B at a 89% premium¹⁷
GSK acquired Bellus Health on April 18, 2023 for $2.0B at a 103% premium¹⁸

The list goes on and on which makes Defence Therapeutics truly an exciting company to follow.

Defence Therapeutics’ (CSE:DTC) (OTC:DCTFF) Leadership Team

Defence Therapeutics’ (CSE:DTC) (OTC:DTCFF) leadership team offers deep technical expertise and a proven track record of wealth creation. The DTC team includes:

Sébastien PlouffeCEO and Director

With 25 years in finance, Plouffe excels in capital markets and project growth. He’s been a VP Senior Investment Advisor at top Canadian firms like BMO and Canaccord, specializing in fundraising and capital management. His diverse expertise spans sectors like biotech and mining.

Dr. Moutih RafeiChief Scientific Officer and Director

An expert in immuno-oncology, Dr. Rafei focuses on cancer therapeutics, T-cell-based therapies and stem cell biology. He holds a PhD from McGill University and has pioneered treatments for severe illnesses. His impactful research has earned over 20 awards and includes numerous publications and patents.

Dr. Sarkis MeterissianDirector

Dr. Meterissian is a tenured Professor of Surgery and Oncology who directs the MUHC Breast Center. His research covers clinical and basic science in breast cancer. He’s collaborated on NSERC-funded projects and serves on various cancer research boards.

Dr. Raimar LöbenbergDirector and Chairman

Dr. Löbenberg holds degrees in Pharmacy and Pharmaceutics and founded the [Medicine] Development and Innovation Centre at the University of Alberta. His research focuses on medication delivery and lung disease treatments. He’s also served on various health advisory panels.

Joseph MeagherDirector, Chairman

Meagher is a CPA and Chartered Director, currently the CFO for multiple public companies. His experience ranges from staff accounting to management roles.

RECAP: 8 Reasons

to Add Defence Therapeutics (CSE:DTC) (OTC:DTCFF) To Your Watchlist

Innovative Patented Technology: Defence Therapeutics’ (CSE:DTC) (OTC:DTCFF) unique US-patented Accum® Technology platform offers superior intracellular medicine delivery, enhancing treatment for a broad spectrum of cancers, even the most challenging ones. The potential to boost any product’s efficacy by a factor of 10-20X is groundbreaking.

Impressive Development and Progress: With two major programs harnessing Accum® Technology for cancer treatment and shot initiatives, Defence Therapeutics has made substantial advancements.

Burgeoning Traction and Product Pipeline: With its patented Accum® Technology at its core, Defence Therapeutics is advancing two programs that address both cancer treatment and shot development, each demonstrating substantial progress.

Solid IP Protection: Defence Therapeutics’ (CSE:DTC) (OTC:DTCFF) expansive global IP landscape comprises 7 unique patent families, covering pivotal domains like ADCs, RNA, DNA, MSCs, mRNA, Delivery, Mixing, Linking, Gene Editing, and CRISPR/Cas9. This paves the way for international licensing possibilities.

Stable Financial Footing: With 43 million shares in circulation, Defence Therapeutics boasts a commendable capital structure. A mere 22-25% makes up the trading float, with the bulk owned by affluent accredited investors, affirming their trust in the company’s long-term potential.

Industry Veterans at the Helm: Defence Therapeutics (CSE:DTC) (OTC:DTCFF) boasts a diverse leadership team, with skills spanning from pre-clinical research to business strategies and regulatory guidelines. Notable members include Dr. Moutih Rafei, a name synonymous with immuno-oncology, and Dr. Raimar Löbenberg, the founder of the University of Alberta’s [Medication] Development and Innovation Centre.

Spotlight from a National Stage: A collaboration with the popular show, Viewpoint, presented by Dennis Quaid, is propelling Defence Therapeutics (CSE:DTC) (OTC:DTCFF) into the national limelight. Their biotech innovations will feature across 170+ U.S. stations starting September 18, 2023.

Promising Research Outcomes: Preclinical studies have yielded remarkable results. Defence Therapeutics reported a 100% remedy rate for established Lymphoma and an 80% triumph against Melanoma.

Wrapping up our deep dive into Defence Therapeutics Inc. (CSE:DTC) (OTC:DTCFF), a company that is truly one-of-a-kind. With their game-changing Accum® Technology, they’re setting the bar high in the field of cancer treatment. This company is not just going after the easy cancers; they’re targeting the ones that need attention the most.

To stay in the loop on what this Company is up to, head over to Defence Therapeutics’ (CSE:DTC) (OTC:DTCFF) official website immediately. You’ll find all the latest updates and news. By keeping tabs on this groundbreaking company, you’ll be the first to know how they’re revolutionizing the way cancer is fought and enhancing the work of other pharmaceutical companies.

Disclaimer

QUICK LINKS TO PREFERRED BROKERAGES

footnotes:
[1] https://globalnews.ca/news/9938796/cancer-cases-young-adults-study/ [2] https://www.mirror.co.uk/news/uk-news/dad-who-staring-death-face-30885572 [3] https://defencetherapeutics.com/accum-technology/ [4] https://defencetherapeutics.com/defences-innovative-therapeutics-are-featured-on-viewpoint-with-dennis-quaid/ [5] Toglenn, CC BY-SA 4.0 , via Wikimedia Commons [6] https://defencetherapeutics.com/defences-broad-and-versatile-accum-technology-platform-focus-on-cancer-therapeutics/ [7]https://tinyurl.com/pcx5ppw6 [8] https://defencetherapeutics.com/wp-content/uploads/2023/04/Q2-23_Defence-Therapeutics-IR-Deck.pdf [9] https://seer.cancer.gov/statfacts/html/pancreas.html [10] https://tinyurl.com/4u64sxcuhttps://tinyurl.com/4u64sxcu [11] https://defencetherapeutics.com/defences-successful-accutox-pre-clinical-efficacy-study-complete-ready-for-phase-i-and-filing/ [12] https://defencetherapeutics.com/wp-content/uploads/2023/04/Defence-Therapeutics-press-release_April_24_US_Patent_Granted_Family_2_Robic-1.pdf [13] https://ca.finance.yahoo.com/news/big-pharma-goes-shopping-biotech-145100817.html?guccounter=2 [14] https://www.bloomberg.com/news/articles/2023-07-28/biogen-to-expand-in-rare-diseases-with-7-3-billion-reata-deal [15] https://www.biopharmadive.com/news/eli-lilly-dice-deal-acquisition-oral-autoimmune-il-17/653332/ [16] https://www.biopharmadive.com/news/eli-lilly-dice-deal-acquisition-oral-autoimmune-il-17/653332/ [17] https://finance.yahoo.com/news/european-swedish-orphan-biovitrum-acquire-134738468.html [18] https://pharmashots.com/15229/gsk-to-acquire-bellus-health-for-20b

Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Defence Therapeutics Inc. Market Jar Media Inc. has or expects to receive from Defence Therapeutics Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) up to one hundred ninety-six thousand and two hundred fifty US dollars for a duration of up to twelve (12) months or until budget exhaustion as dictated by Defence Therapeutics Inc.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Defence Therapeutics Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Defence Therapeutics Inc.’s industry; (b) market opportunity; (c) Defence Therapeutics Inc.’s business plans and strategies; (d) services that Defence Therapeutics Inc. intends to offer; (e) Defence Therapeutics Inc.’s milestone projections and targets; (f) Defence Therapeutics Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Defence Therapeutics Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Defence Therapeutics Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Defence Therapeutics Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Defence Therapeutics Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Defence Therapeutics Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Defence Therapeutics Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Defence Therapeutics Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Defence Therapeutics Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Defence Therapeutics Inc.’s business operations (e) Defence Therapeutics Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Defence Therapeutics Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Defence Therapeutics Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Defence Therapeutics Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Defence Therapeutics Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Defence Therapeutics Inc. or such entities and are not necessarily indicative of future performance of Defence Therapeutics Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

PressReach

SEARCH FOR AN ARTICLE

PressReach

PressReach

Groundbreaking ARM Shot Set to Redefine Cancer Therapies

Breaking News

Developing the First-of-its-Kind Scalable Solution Solving Previous Cancer Treatment Challenges

Press Releases

Accelerated Cancer Shot Development on the Path Towards Approval

US Patent Granted to Defence for Wide-Ranging Accum® Medicine Enhancer Tech

Attractive Capital Structure with Loyal Investors and Partners

Big Pharma on a Buying Spree: Biotech Takeovers Poised to Soar

Defence Therapeutics’ (CSE:DTC) (OTC:DCTFF) Leadership Team

QUICK LINKS TO PREFERRED BROKERAGES

More News From This Company

Defence Therapeutics Inc.

Company News

Don't Hestitate! Get The Corporate Presentation Now

PLUS

PressReach

Breaking News

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Developing the First-of-its-Kind Scalable Solution Solving Previous Cancer Treatment Challenges

Press Releases

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Accelerated Cancer Shot Development on the Path Towards Approval

US Patent Granted to Defence for Wide-Ranging Accum® Medicine Enhancer Tech

Attractive Capital Structure with Loyal Investors and Partners

Big Pharma on a Buying Spree: Biotech Takeovers Poised to Soar

Defence Therapeutics’ (CSE:DTC) (OTC:DCTFF) Leadership Team

SUBSCRIBE FOR TRADING INSIGHTS AND ALERTS. STAY AHEAD.

Get Money Saving Tips

QUICK LINKS TO PREFERRED BROKERAGES

More News From This Company

Defence Therapeutics Inc.

Company News

Don't Hestitate! Get The Corporate Presentation Now

PLUS

Get Money
Saving Tips